Estimating the burden of disease from unsafe injections in India: A cost-benefit assessment of the auto-disable syringe in a country with low blood-borne virus prevalence
Background: Unsafe medical injections are a prevalent risk factor for viral hepatitis and HIV in India. Objectives: This review undertakes a cost-benefit assessment of the auto-disable syringe, now being introduced to prevent the spread of hepatitis B virus, hepatitis C virus, and human immunodefici...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2012-01-01
|
| Series: | Indian Journal of Community Medicine |
| Subjects: | |
| Online Access: | http://www.ijcm.org.in/article.asp?issn=0970-0218;year=2012;volume=37;issue=2;spage=89;epage=94;aulast=Reid |
| _version_ | 1811239678409441280 |
|---|---|
| author | Savanna Reid |
| author_facet | Savanna Reid |
| author_sort | Savanna Reid |
| collection | DOAJ |
| description | Background: Unsafe medical injections are a prevalent risk factor for viral hepatitis and HIV in India. Objectives: This review undertakes a cost-benefit assessment of the auto-disable syringe, now being introduced to prevent the spread of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus (HIV). Materials and Methods: The World Health Organization methods for modeling the global burden of disease from unsafe medical injections are reproduced, correcting for the concentrated structure of the HIV epidemic in India. A systematic review of risk factor analyses in India that investigate injection risks is used in the uncertainty analysis. Results: The median population attributable fraction for hepatitis B carriage associated with recent injections is 46%, the median fraction of hepatitis C infections attributed to unsafe medical injections is 38%, and the median fraction of incident HIV infections attributed to medical injections is 12% in India. The modeled incidence of blood-borne viruses suggests that introducing the auto-disable syringe will impose an incremental cost of $46-48 per disability adjusted life year (DALY) averted. The epidemiological evidence suggests that the incremental cost of introducing the auto-disable syringe for all medical injections is between $39 and $79 per DALY averted. Conclusions: The auto-disable syringe is a cost-effective alternative to the reuse of syringes in a country with low prevalence of blood-borne viruses. |
| first_indexed | 2024-04-12T13:05:18Z |
| format | Article |
| id | doaj.art-e5832a8706dc485099935a327571c473 |
| institution | Directory Open Access Journal |
| issn | 0970-0218 1998-3581 |
| language | English |
| last_indexed | 2024-04-12T13:05:18Z |
| publishDate | 2012-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Community Medicine |
| spelling | doaj.art-e5832a8706dc485099935a327571c4732022-12-22T03:32:04ZengWolters Kluwer Medknow PublicationsIndian Journal of Community Medicine0970-02181998-35812012-01-01372899410.4103/0970-0218.96093Estimating the burden of disease from unsafe injections in India: A cost-benefit assessment of the auto-disable syringe in a country with low blood-borne virus prevalenceSavanna ReidBackground: Unsafe medical injections are a prevalent risk factor for viral hepatitis and HIV in India. Objectives: This review undertakes a cost-benefit assessment of the auto-disable syringe, now being introduced to prevent the spread of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus (HIV). Materials and Methods: The World Health Organization methods for modeling the global burden of disease from unsafe medical injections are reproduced, correcting for the concentrated structure of the HIV epidemic in India. A systematic review of risk factor analyses in India that investigate injection risks is used in the uncertainty analysis. Results: The median population attributable fraction for hepatitis B carriage associated with recent injections is 46%, the median fraction of hepatitis C infections attributed to unsafe medical injections is 38%, and the median fraction of incident HIV infections attributed to medical injections is 12% in India. The modeled incidence of blood-borne viruses suggests that introducing the auto-disable syringe will impose an incremental cost of $46-48 per disability adjusted life year (DALY) averted. The epidemiological evidence suggests that the incremental cost of introducing the auto-disable syringe for all medical injections is between $39 and $79 per DALY averted. Conclusions: The auto-disable syringe is a cost-effective alternative to the reuse of syringes in a country with low prevalence of blood-borne viruses.http://www.ijcm.org.in/article.asp?issn=0970-0218;year=2012;volume=37;issue=2;spage=89;epage=94;aulast=ReidCost-benefithepatitis B virushepatitis C virusHIVinjections |
| spellingShingle | Savanna Reid Estimating the burden of disease from unsafe injections in India: A cost-benefit assessment of the auto-disable syringe in a country with low blood-borne virus prevalence Indian Journal of Community Medicine Cost-benefit hepatitis B virus hepatitis C virus HIV injections |
| title | Estimating the burden of disease from unsafe injections in India: A cost-benefit assessment of the auto-disable syringe in a country with low blood-borne virus prevalence |
| title_full | Estimating the burden of disease from unsafe injections in India: A cost-benefit assessment of the auto-disable syringe in a country with low blood-borne virus prevalence |
| title_fullStr | Estimating the burden of disease from unsafe injections in India: A cost-benefit assessment of the auto-disable syringe in a country with low blood-borne virus prevalence |
| title_full_unstemmed | Estimating the burden of disease from unsafe injections in India: A cost-benefit assessment of the auto-disable syringe in a country with low blood-borne virus prevalence |
| title_short | Estimating the burden of disease from unsafe injections in India: A cost-benefit assessment of the auto-disable syringe in a country with low blood-borne virus prevalence |
| title_sort | estimating the burden of disease from unsafe injections in india a cost benefit assessment of the auto disable syringe in a country with low blood borne virus prevalence |
| topic | Cost-benefit hepatitis B virus hepatitis C virus HIV injections |
| url | http://www.ijcm.org.in/article.asp?issn=0970-0218;year=2012;volume=37;issue=2;spage=89;epage=94;aulast=Reid |
| work_keys_str_mv | AT savannareid estimatingtheburdenofdiseasefromunsafeinjectionsinindiaacostbenefitassessmentoftheautodisablesyringeinacountrywithlowbloodbornevirusprevalence |